Durect (DRRX) AI Stock Analysis

• Market Cap: $59.31M
• Dividend Yield: N/A
• Average Volume (3M): 2.24M
• Price to Earnings (P/E): ―
• Beta (1Y): -1.54
• Revenue Growth: -62.57%
• EPS Growth: 11.60%
• Country: US
• Employees: 21
• Sector: Healthcare
• Sector Strength: 52
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.07
• Shares Outstanding: 31,054,188
• 10 Day Avg. Volume: 485,599
• 30 Day Avg. Volume: 2,236,484
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.25
• Enterprise Value/Revenue: 3.07
• Enterprise Value/Gross Profit: 3.83
• Enterprise Value/Ebitda: -0.95
• 1Y Price Target: $2.25
• Price Target Upside: 17.80% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 45 Neutral
• Price Target: $2.00 ▲(4.71% Upside)

Durect's overall stock score reflects significant financial challenges and unattractive valuation. The merger with Bausch Health offers potential strategic benefits, but the risk of Nasdaq delisting remains a major concern. Mixed technical indicators further complicate the investment outlook.

Positive Factors

Clinical Trial Success

90-day mortality reductions were statistically significant in U.S. patients treated with larsucosterol at either dose in the Phase 2b AHFIRM trial.

Regulatory Approval

The FDA has granted larsucosterol Fast Track Designation and Breakthrough Therapy Designation for the treatment of alcohol-associated hepatitis.

Negative Factors

Financial Risk

DURECT is viewed as a significant 'going concern' risk with its current cash runway that extends into 1Q25.

Funding Challenges

There remains significant uncertainty regarding the available options to finance the Phase 3 study.

Durect Business Overview & Revenue Model

Company Description

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

How the Company Makes Money

Durect generates revenue primarily through the development and commercialization of its drug candidates. This includes potential milestone payments from partnerships with larger pharmaceutical companies, royalties from product sales, and licensing agreements. The company may also receive funding through grants and collaborations aimed at advancing its clinical programs. Notably, strategic alliances with larger biotechnology firms can provide upfront payments, research funding, and a share of future profits, thus contributing to Durect's overall earnings.

Durect Financial Statement Overview

Summary

Durect's financial performance is weak, marked by significant revenue decline, persistent losses, and negative cash flows. The balance sheet shows high leverage and reduced equity, with inefficiencies in operations highlighted by negative cash flows. Without substantial improvements, financial stability remains a concern.

Income Statement

Durect has experienced a significant revenue decline from 2020 to 2024, with total revenue dropping from $30.1M to $2.03M. Gross profit margins remain positive but are overshadowed by persistent negative EBIT and net profit margins, indicating ongoing operational challenges. Consistently negative EBITDA and net income reflect struggles in cost management and profitability.

Balance Sheet

The company's balance sheet shows a decreasing trend in total assets and equity from 2019 to 2024, with stockholders' equity shrinking significantly. The debt-to-equity ratio remains relatively high, indicating leverage concerns, although recent efforts to reduce debt are noted. The equity ratio has deteriorated, suggesting a reduced buffer for absorbing financial shocks.

Cash Flow

Durect's cash flow situation is concerning, with consistently negative operating and free cash flow over the years. Despite some improvement in investing activities, the operating cash flow to net income ratio remains negative, highlighting inefficiencies in translating income into cash flow. Financing activities have not sufficiently offset the negative cash flows from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.87M	2.03M	8.55M	19.28M	13.98M	30.11M
Gross Profit	3.91M	1.95M	6.83M	17.70M	12.02M	28.70M
EBITDA	-15.83M	-18.83M	-24.68M	-32.78M	-33.98M	-11.80M
Net Income	-4.91M	-8.32M	-27.62M	-35.33M	-36.27M	-13.43M
Balance Sheet
Total Assets	14.36M	18.35M	45.19M	60.10M	91.99M	75.64M
Cash, Cash Equivalents and Short-Term Investments	8.26M	11.80M	29.68M	43.48M	69.81M	40.73M
Total Debt	1.98M	2.21M	20.75M	23.26M	24.30M	25.82M
Total Liabilities	9.01M	9.22M	30.41M	35.12M	34.21M	35.53M
Stockholders Equity	5.35M	9.13M	14.78M	24.98M	57.78M	40.12M
Cash Flow
Free Cash Flow	-15.87M	-19.09M	-34.47M	-26.39M	-37.51M	-38.91M
Operating Cash Flow	-15.86M	-19.09M	-34.41M	-26.28M	-37.31M	-38.70M
Investing Cash Flow	19.43M	18.04M	-1.17M	19.84M	15.31M	9.43M
Financing Cash Flow	-14.85M	-16.35M	20.50M	83.00K	50.53M	15.66M

Durect Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.91
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DRRX, the sentiment is Positive. The current price of 1.91 is below the 20-day moving average (MA) of 1.91, above the 50-day MA of 1.33, and above the 200-day MA of 0.90, indicating a neutral trend. The MACD of 0.15 indicates Positive momentum. The RSI at 73.30 is Negative, neither overbought nor oversold. The STOCH value of 36.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DRRX.

Durect Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.95B	-0.40	-41.62%	2.21%	22.29%	-1.85%
TXMD	47 Neutral	$12.50M	―	-1.98%	―	156.93%	92.75%
DRRX	45 Neutral	$59.31M	―	-291.74%	―	-62.57%	11.60%
SISI	―	$227.41M	―	-58.27%	―	―	―
KALA	31 Underperform	$102.16M	―	-708.34%	―	―	51.27%
SXTC	―	$186.80M	0.07	-22.50%	―	―	―
IXHL	39 Underperform	$49.19M	―	-201.88%	―	―	―

Durect Corporate Events

Durect Extends Tender Offer Deadline in Merger

On July 28, 2025, Durect Corporation entered into a Merger Agreement with Bausch Health Americas, Inc. and its subsidiary, BHC Lyon Merger Sub, Inc. An amendment to this agreement was made on August 8, 2025, extending the deadline for the tender offer for Durect’s outstanding shares from August 11 to August 12, 2025. This extension may impact the company’s operations and stakeholder interests by providing additional time for the tender process.

The most recent analyst rating on (DRRX) stock is a Buy with a $8.50 price target. To see the full list of analyst forecasts on Durect stock, see the DRRX Stock Forecast page.

Durect Merges with Bausch Health for $1.75/Share

On July 28, 2025, DURECT Corporation entered into a merger agreement with Bausch Health Americas, Inc., where Bausch will acquire DURECT for $1.75 per share in cash, with potential additional milestone payments. This acquisition, expected to close in the third quarter of 2025, will bolster Bausch Health’s commitment to hepatology and liver disease treatments, particularly with the promising development of Larsucosterol for alcoholic hepatitis, a condition with no current FDA-approved treatments. The merger reflects strategic alignment and potential value for stakeholders, enhancing Bausch Health’s portfolio in liver disease therapeutics.

The most recent analyst rating on (DRRX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Durect stock, see the DRRX Stock Forecast page.

Durect Receives Nasdaq Delisting Notice Extension

DURECT Corporation received a notice from Nasdaq on January 9, 2025, indicating that its stock price had fallen below the minimum bid price requirement of $1.00 per share for 30 consecutive trading days. The company was initially given until July 8, 2025, to comply, and later received an additional 180-day grace period until January 5, 2026. DURECT plans to monitor its stock price and may implement a reverse stock split if necessary to meet the requirements, as failure to regain compliance could result in delisting.

The most recent analyst rating on (DRRX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Durect stock, see the DRRX Stock Forecast page.